Promising research using a PARP inhibitor to treat metastatic breast cancer in people with an inherited PALB2 mutation or a tumor mutation in BRCA1 or BRCA2
Full article:

Early results of a small study showed that women with metastatic breast cancer and an inherited  mutation in PALB2 or an acquired tumor mutation in BRCA1 or BRCA2 benefitted from the PARP inhibitor olaparib (Lynparza). (6/18/20)

Questions To Ask Your Health Care Provider

Open Clinical Trials

The following are studies looking at PARP inhibitors as treatment for advanced breast cancer: 

A number of other clinical trials for treating patients with metastatic breast cancer can be found here.

The following studies are looking at treatment for people with advanced solid tumors. 



FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.